Galectin Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galectin Therapeutics Inc.
China Pharma Eyes Brighter SE Asia Markets Amid US Entry Shadows
Junshi is the latest Chinese company to announce plans to expand into Southeast Asia, where its compatriot firms are also eyeing large market potential and are set to benefit from less stringent reviews of China-only clinical data due to fewer questions around ethnic differences versus the US.
Will Biosimilar Competition And Product-Hopping Save Regeneron’s Eylea Or Cancel Each Other Out?
Biosimilar entrants look to help protect Regeneron’s currently marketed form of Eylea from the US’s new price negotiation law. But it likely hinges on how CMS views the company’s product-hopping plan.
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
Asia Deal Watch: Junshi, Rxilient Form Joint Venture Around Toripalimab
Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.
- Drug Delivery
- Other Names / Subsidiaries
- Galectin Sciences, LLC
- Pro-Pharmaceuticals Inc.
- Galectin Therapeutics Security Corp.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.